Marker Therapeutics reports complete response in first lymphoma patient treated with MT-601 after CAR T relapse

Marker Therapeutics, Inc.

First APOLLO trial patient with DLBCL, after 4 prior therapies including CAR T, achieved complete metabolic response at 8 weeks post 2nd MT-601 infusion.
MT-601 dosed at 200 million cells without prior lymphodepletion; no treatment-related adverse events above Grade 1.
Up to 60% of CAR T patients relapse within one year, underscoring potential of MT-601 in this setting.
Phase 1 APOLLO trial continues to enroll additional participants to evaluate safety and efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.